Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Influenza A virus neuraminidase (NA) is a surface glycoprotein enzyme critical for the viral life cycle. It is essential for efficient viral replication, spread, and pathogenesis. NA acts as an exosialidase, cleaving α-ketosidic linkages between sialic acid and adjacent sugar residues, facilitating release of progeny viruses from infected cells and preventing self-aggregation. Neuraminidase inhibitors are key antiviral drugs that target NA's enzymatic activity, blocking viral release.
Competitive inhibition of neuraminidase enzymatic activity, blocking viral release from infected cells.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Influenza A Virus Neuraminidase (NA).